Research programme: recombinant coagulation factors - CSL Behring

Drug Profile

Research programme: recombinant coagulation factors - CSL Behring

Alternative Names: CSL 626; CSL 650; CSL626 rD'D3-FP; rvWF-FP

Latest Information Update: 28 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Factor VIIa stimulants; Von Willebrand factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 28 Feb 2017 CSL 626 rD'D3-FP is in preclinical development for haemophilia (CSL group pipeline, February 2017)
  • 03 Apr 2012 rvWF-FP is still in preclinical development for haemophilia in the US
  • 08 Dec 2011 CSL initiates research programme for rvWF-FP in Haemophilia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top